CRVO
MCID: CNT016
MIFTS: 50

Central Retinal Vein Occlusion (CRVO)

Categories: Cardiovascular diseases, Eye diseases, Rare diseases

Aliases & Classifications for Central Retinal Vein Occlusion

MalaCards integrated aliases for Central Retinal Vein Occlusion:

Name: Central Retinal Vein Occlusion 12 60 56 15 74
Crvo 60

Characteristics:

Orphanet epidemiological data:

60
central retinal vein occlusion
Prevalence: 1-5/10000 (Europe); Age of onset: Adult,Elderly;

Classifications:



External Ids:

Disease Ontology 12 DOID:2450
ICD9CM 36 362.35
NCIt 51 C118859
SNOMED-CT 69 68478007
ICD10 34 H34.81
ICD10 via Orphanet 35 H34.8
UMLS via Orphanet 75 C0154841
Orphanet 60 ORPHA411527
UMLS 74 C0154841

Summaries for Central Retinal Vein Occlusion

MalaCards based summary : Central Retinal Vein Occlusion, also known as crvo, is related to macular retinal edema and macular dystrophy, dominant cystoid. An important gene associated with Central Retinal Vein Occlusion is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Bevacizumab and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are homeostasis/metabolism and cardiovascular system

Wikipedia : 77 The central retinal vein is the venous equivalent of the central retinal artery and, like that blood... more...

Related Diseases for Central Retinal Vein Occlusion

Diseases in the Retinal Vein Occlusion family:

Central Retinal Vein Occlusion

Diseases related to Central Retinal Vein Occlusion via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 282)
# Related Disease Score Top Affiliating Genes
1 macular retinal edema 31.8 IL6 VEGFA
2 macular dystrophy, dominant cystoid 30.7 SERPINF1 VEGFA
3 arteriovenous malformation 30.6 IL6 VEGFA
4 macular holes 30.1 SERPINF1 VEGFA
5 exfoliation syndrome 30.0 LOXL1 MTHFR
6 factor xii deficiency 30.0 APOH F5 SERPINC1
7 hemophilia b 30.0 F2 SERPINC1
8 retinal vascular disease 30.0 MTHFR SERPINF1 VEGFA
9 branch retinal artery occlusion 29.9 APOH F2 MTHFR SERPINC1
10 arteritic anterior ischemic optic neuropathy 29.9 F2 F5 MTHFR
11 temporal arteritis 29.9 APOH IL6
12 thrombocytosis 29.9 F2 IL6 SERPINC1
13 eclampsia 29.9 F2 MTHFR SERPINC1
14 von willebrand's disease 29.8 F2 F5
15 nonarteritic anterior ischemic optic neuropathy 29.8 F2 F5 MTHFR SERPINC1
16 purpura 29.8 APOH F2 IL6 SERPINC1
17 sneddon syndrome 29.8 APOH F2 SERPINC1
18 ischemic optic neuropathy 29.7 APOH F2 F5 MTHFR SERPINC1
19 protein s deficiency 29.7 APOH F2 F5 MTHFR SERPINC1
20 thrombophilia 29.7 APOH F2 F5 MTHFR SERPINC1
21 antiphospholipid syndrome 29.7 APOH F2 F5 MTHFR SERPINC1
22 diabetic macular edema 29.6 IL6 SERPINF1 VEGFA
23 protein c deficiency 29.6 F2 F5 MTHFR SERPINC1
24 retinal vein occlusion 29.5 APOH F2 F5 IL6 LOXL1 MTHFR
25 thrombosis 29.4 APOH F2 F5 MTHFR SERPINC1
26 antithrombin iii deficiency 29.2 APOH F2 F5 MTHFR SERPINC1
27 thrombophilia due to activated protein c resistance 29.2 APOH F2 F5 MTHFR SERPINC1
28 retinal artery occlusion 29.1 APOH F2 F5 IL6 MTHFR SERPINC1
29 heart disease 29.1 F2 IL6 MTHFR SERPINC1 VEGFA
30 retinal vascular occlusion 28.9 APOH F2 F5 MTHFR SERPINC1 VEGFA
31 vascular disease 28.8 APOH F2 F5 IL6 MTHFR SERPINC1
32 hellp syndrome 28.8 APOH F2 F5 IL6 MTHFR SERPINC1
33 pre-eclampsia 28.4 APOH F2 F5 IL6 MTHFR SERPINC1
34 neovascular glaucoma 10.5
35 optic nerve disease 10.4
36 ischemia 10.4
37 neuropathy 10.4
38 inferior vena cava interruption 10.4 F5 MTHFR
39 amaurosis fugax 10.4 F5 MTHFR
40 retinal detachment 10.3
41 hemifacial spasm 10.3 MTHFR VEGFA
42 may-thurner syndrome 10.3 APOH F5
43 acanthamoeba keratitis 10.3 APOH F5
44 leukemia 10.3
45 retinitis 10.3
46 pregnancy loss, recurrent 1 10.3 APOH F5
47 carotid artery occlusion 10.3 APOH F5
48 sticky platelet syndrome 10.3 F5 SERPINC1
49 schizencephaly 10.3 F5 MTHFR
50 systemic lupus erythematosus 10.3

Comorbidity relations with Central Retinal Vein Occlusion via Phenotypic Disease Network (PDN):


Hypertension, Essential

Graphical network of the top 20 diseases related to Central Retinal Vein Occlusion:



Diseases related to Central Retinal Vein Occlusion

Symptoms & Phenotypes for Central Retinal Vein Occlusion

MGI Mouse Phenotypes related to Central Retinal Vein Occlusion:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.97 APOH F2 F5 IL6 LOXL1 MTHFR
2 cardiovascular system MP:0005385 9.91 F2 F5 IL6 SERPINC1 SERPINF1 VEGFA
3 digestive/alimentary MP:0005381 9.8 F2 IL6 LOXL1 SERPINF1 VEGFA
4 integument MP:0010771 9.8 F2 F5 IL6 LOXL1 MTHFR VEGFA
5 nervous system MP:0003631 9.76 F2 F5 IL6 LOXL1 MTHFR SERPINC1
6 liver/biliary system MP:0005370 9.65 F5 IL6 MTHFR SERPINC1 VEGFA
7 reproductive system MP:0005389 9.5 F2 IL6 LOXL1 MTHFR SERPINC1 SERPINF1
8 vision/eye MP:0005391 9.02 IL6 MTHFR SERPINC1 SERPINF1 VEGFA

Drugs & Therapeutics for Central Retinal Vein Occlusion

Drugs for Central Retinal Vein Occlusion (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
2
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 124-94-7 31307
3
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 347396-82-1 459903
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 1177-87-3
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-02-2 5743
6
Histidine Approved, Nutraceutical Phase 4 71-00-1 6274
7
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
8 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Triamcinolone hexacetonide Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
11 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
12 Antineoplastic Agents, Immunological Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
14 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
15 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
16 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
17 Triamcinolone diacetate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
18 triamcinolone acetonide Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
19 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
21 Mitogens Phase 4,Phase 3,Phase 1,Phase 2
22 Endothelial Growth Factors Phase 4,Phase 3,Phase 1,Phase 2
23
protease inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
24 Autonomic Agents Phase 4,Phase 2,Phase 3,Not Applicable
25 BB 1101 Phase 4,Phase 2,Phase 3,Not Applicable
26 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
27 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
28 Antiemetics Phase 4,Phase 2,Phase 3,Not Applicable
29 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Not Applicable
30 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
31 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
32 Dexamethasone 21-phosphate Phase 4
33
Atorvastatin Approved Phase 3 134523-00-5 60823
34
Povidone-iodine Approved Phase 3,Not Applicable 25655-41-8
35
Nicotinamide Approved, Investigational Phase 2, Phase 3,Phase 3 98-92-0 936
36
Povidone Approved Phase 3 9003-39-8
37
Iodine Approved, Investigational Phase 3 7553-56-2 807
38
Niacin Approved, Investigational, Nutraceutical Phase 2, Phase 3,Phase 3 59-67-6 938
39
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
40 Anticholesteremic Agents Phase 3
41 Lipid Regulating Agents Phase 3,Phase 2
42 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
43 Antimetabolites Phase 3,Phase 2
44 Hypolipidemic Agents Phase 3,Phase 2
45 Antibiotics, Antitubercular Phase 3,Not Applicable
46 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2,Not Applicable
47 Vasodilator Agents Phase 2, Phase 3
48 Vitamins Phase 2, Phase 3
49 Nicotinic Acids Phase 2, Phase 3
50 Trace Elements Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 98)
# Name Status NCT ID Phase Drugs
1 Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO Unknown status NCT00566761 Phase 4 bevacizumab and triamcinolone
2 Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy Unknown status NCT01857544 Phase 4 Aflibercept
3 Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen Unknown status NCT02274259 Phase 4 Aflibercept;Ranibizumab
4 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion Unknown status NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
5 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Unknown status NCT02522897 Phase 4 Ranibizumab
6 Hemodilution Versus Ranibizumab in Early-onset Central Retinal Vein Occlusion Completed NCT01448018 Phase 4 ranibizumab
7 NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions Completed NCT01870427 Phase 4 Aflibercept (2.0 mg)
8 Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Completed NCT01710839 Phase 4 0.5mg Ranibizumab
9 Intraocular Bevacizumab (Avastin) for Rubeosis Iridis Completed NCT00557232 Phase 4 bevacizumab
10 Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO Completed NCT01580020 Phase 4 Dexamethasone
11 A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion Completed NCT01277302 Phase 4 Ranibizumab
12 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO Completed NCT02503540 Phase 4 Aflibercept
13 Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO Active, not recruiting NCT02800642 Phase 4 Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
14 Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema Terminated NCT02684084 Phase 4 Ozurdex;Lucentis
15 Atorvastatin for the Treatment of Retinal Vein Occlusion Unknown status NCT00517257 Phase 3 Atorvastatin;Placebo
16 Bevacizumab for Central Retinal Vein Occlusion Study Completed NCT00906685 Phase 3 bevacizumab;Sham bevacizumab injection
17 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) Completed NCT00943072 Phase 3 Sham
18 Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) Completed NCT01976312 Phase 3 Ranibizumab 0.5 mg
19 Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion Completed NCT01295112 Phase 2, Phase 3 Active bevacizumab and Sham dexamethasone;Active bevacizumab and Active dexamethasone
20 Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion Completed NCT01535261 Phase 3 Ranibizumab 0.5 mg/0.05 ml
21 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) Completed NCT01012973 Phase 3
22 Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO) Completed NCT01396083 Phase 3 Ranibizumab;Dexamethasone implant and sham injections
23 A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE) Completed NCT00485836 Phase 3 Sham injection;Ranibizumab injection 0.3 mg;Ranibizumab injection 0.5 mg
24 The ROVO Study: Radial Optic Neurotomy for CVO Completed NCT00532142 Phase 2, Phase 3 Intravitreal Triamcinolone
25 A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO Completed NCT00567697 Phase 3 ranibizumab;ranibizumab
26 Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion Completed NCT01377597 Phase 3 ranibizumab
27 The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study Completed NCT00105027 Phase 3 intravitreal triamcinolone injection;intravitreal triamcinolone injection
28 Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion Completed NCT01198327 Phase 3 ranibizumab
29 Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions Completed NCT00500045 Phase 2, Phase 3 nicotinic acid
30 Safety and Effectiveness of Bevacizumab Intravitreal Injections in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion Completed NCT00970957 Phase 3 Avastin Intravitreal Injection;Sham Avastin Intravitreal Injection
31 Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage Completed NCT00106132 Phase 3 Triamcinolone Acetonide
32 Bevacizumab Versus Ranibizumab for Diabetic Retinopathy Completed NCT00545870 Phase 3 bevacizumab;Ranibizumab
33 Ozurdex for Retinal Vein Occlusion Study (ORVO Study) Completed NCT01790685 Phase 2, Phase 3 dexamethasone implant
34 Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion Recruiting NCT03223714 Phase 3 Conbercept Ophthalmic Injection;sham injection
35 DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME Recruiting NCT03321513 Phase 3 intravitreous aflibercept;Bevacizumab + Deferred Aflibercept Group
36 Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Active, not recruiting NCT01969708 Phase 3 aflibercept;bevacizumab
37 Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion Not yet recruiting NCT03810313 Phase 3 Brolucizumab 6 mg;Aflibercept 2 mg
38 Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG Not yet recruiting NCT02947867 Phase 2, Phase 3 aganirsen
39 Prevention of Retinal Non-perfusion in Central Retinal Vein Occlusion by Hydroxycarbamide Treatment. Unknown status NCT02957760 Phase 2 Hydroxycarbamid
40 Hyperbaric Chamber for Central Retinal Vein Occlusion (CRVO) Patients Unknown status NCT02405741 Phase 2
41 Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO) Unknown status NCT01178697 Phase 2 Bevasizumab;Triamcinolone Acetonide
42 Efficacy and Safety of Lucentis for Clinically Significant Macular Edema Secondary to Central Retinal Vein Occlusion Unknown status NCT01123564 Phase 2 ranibizumab
43 Intravitreal Avastin Versus Intravitreal Avastin and Triamcinolone in Central Retinal Vein Occlusion(CRVO) Unknown status NCT00370630 Phase 2 Avastin (Bevacizumab) and triamcinolone
44 Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion Completed NCT02614937 Phase 1, Phase 2 ranibizumab;Squalamine Lactate Ophthalmic Solution, 0.2%
45 Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion Completed NCT01724554 Phase 1, Phase 2 Intravitreal Aflibercept Injection
46 Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) Completed NCT00088283 Phase 2 pegaptanib sodium
47 Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab Completed NCT01471691 Phase 1, Phase 2 ranibizumab 0.5mg;ranibizumab 1.0mg
48 Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study Completed NCT02620618 Phase 1, Phase 2 Intravitreal Infliximab
49 Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy Completed NCT01971190 Phase 2 Intravitreal Aflibercept injection;Sham injection
50 Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions Completed NCT01003106 Phase 1, Phase 2 Ranibizumab 0.5mg (monthly);Ranibizumab 2.0mg (monthly);Pro re nata (prn) ranibizumab

Search NIH Clinical Center for Central Retinal Vein Occlusion

Genetic Tests for Central Retinal Vein Occlusion

Anatomical Context for Central Retinal Vein Occlusion

MalaCards organs/tissues related to Central Retinal Vein Occlusion:

42
Eye, Retina, Endothelial, Bone, Heart, Myeloid, Liver

Publications for Central Retinal Vein Occlusion

Articles related to Central Retinal Vein Occlusion:

(show top 50) (show all 1063)
# Title Authors Year
1
Malignant optic glioma masked by suspected optic neuritis and central retinal vein occlusion. ( 30450148 )
2019
2
Long-term management of non-ischemic central retinal vein occlusion with fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN®). ( 30643869 )
2019
3
Efficacy of panretinal laser in ischemic central retinal vein occlusion: A systematic review. ( 30651879 )
2019
4
Bilateral simultaneous central retinal vein occlusion revealing Waldenström's macroglobulinemia. ( 30665794 )
2019
5
Effect of Aflibercept on Cystoid Macular Edema Associated with Central Retinal Vein Occlusion. Results from a District Hospital in the United Kingdom. ( 30795014 )
2019
6
Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusionrelated macular oedema: a prospective randomized comparison - comment. ( 30801910 )
2019
7
Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion related macular oedema: a prospective randomized comparison - response. ( 30816598 )
2019
8
Central retinal vein occlusion in a patient with breast carcinoma. ( 30828514 )
2019
9
Predictors of Neovascular Glaucoma in Central Retinal Vein Occlusion. ( 30862502 )
2019
10
Outcome After Exchange Transfusion for Central Retinal Vein Occlusion Associated With Extensive Capillary and Arteriolar Nonperfusion in a Patient With Hemoglobin SS Disease. ( 30896741 )
2019
11
Central retinal vein occlusion in temporal arteritis: red sign or red herring? ( 29361164 )
2018
12
Effects of Dexamethasone Implant on Multifocal Electroretinography in Central Retinal Vein Occlusion. ( 29403585 )
2018
13
YC-1 Inhibits VEGF and Inflammatory Mediators Expression on Experimental Central Retinal Vein Occlusion in Rhesus Monkey. ( 29364731 )
2018
14
USE OF THE ISCHEMIC INDEX ON WIDEFIELD FLUORESCEIN ANGIOGRAPHY TO CHARACTERIZE A CENTRAL RETINAL VEIN OCCLUSION AS ISCHEMIC OR NONISCHEMIC. ( 29474305 )
2018
15
Comparing Cytokine Kinetics between Ranibizumab and Aflibercept in Central Retinal Vein Occlusion with Macular Edema. ( 29804112 )
2018
16
Cardiovascular risk factors in patients with combined central retinal vein occlusion and cilioretinal artery occlusion: Case report. ( 29505511 )
2018
17
Elevated lipocalin-2 level in aqueous humor of patients with central retinal vein occlusion. ( 29572586 )
2018
18
INJECTION FREQUENCY OF AFLIBERCEPT VERSUS RANIBIZUMAB IN A TREAT-AND-EXTEND REGIMEN FOR CENTRAL RETINAL VEIN OCCLUSION: A Randomized Clinical Trial. ( 29624543 )
2018
19
The short-term efficacy of intravitreal ranibizumab, aflibercept and dexamethasone implant in the treatment of macular edema due to non-ischemic central retinal vein occlusion. ( 29550932 )
2018
20
Sequential Observations of Conversion from Nonischemic to Ischemic Central Retinal Vein Occlusion Using Optical Coherence Tomography Angiography. ( 29850324 )
2018
21
Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months. ( 29185099 )
2018
22
Intravitreal dexamethasone implant versus triamcinolone acetonide for macular oedema of central retinal vein occlusion: quantifying efficacy and safety. ( 29632703 )
2018
23
Aflibercept Versus Bevacizumab and/or Ranibizumab for Recurrent Macular Edema Secondary to Central Retinal Vein Occlusion. ( 29447089 )
2018
24
Swept-Source OCT Angiographic Imaging of a Central Retinal Vein Occlusion During Pregnancy. ( 29554389 )
2018
25
Anomalous coagulation factors in non-arteritic anterior ischemic optic neuropathy with central retinal vein occlusion: A case report. ( 29642215 )
2018
26
Correlation between macular ganglion cell-inner plexiform layer thickness and visual acuity after resolution of the macular edema secondary to central retinal vein occlusion. ( 29487816 )
2018
27
Pre-treatment clinical features in central retinal vein occlusion that predict visual outcome following intravitreal ranibizumab. ( 29426292 )
2018
28
Combined central retinal vein occlusion and branch retinal artery occlusion. ( 30451204 )
2018
29
RETINAL BLOOD FLOW AFTER INTRAVITREAL BEVACIZUMAB IS A PREDICTIVE FACTOR FOR OUTCOMES OF MACULAR EDEMA ASSOCIATED WITH CENTRAL RETINAL VEIN OCCLUSION. ( 28151838 )
2018
30
ISCHEMIC CENTRAL RETINAL VEIN OCCLUSION IN THE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ERA. ( 28207609 )
2018
31
Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab. ( 28405787 )
2018
32
CENTRAL RETINAL VEIN OCCLUSION IN YOUNG INDIVIDUALS: A Comparison of Risk Factors and Clinical Outcomes. ( 30085977 )
2018
33
Extended Injection Intervals after Switching from Ranibizumab to Aflibercept in Macular Edema due to Central Retinal Vein Occlusion. ( 30116635 )
2018
34
Central retinal vein occlusion revealing celiac disease: The first report of two cases from India. ( 30127151 )
2018
35
Ocriplasmin in the Treatment of Vitreomacular Traction in a Patient with Central Retinal Vein Occlusion: A Case Report. ( 30140222 )
2018
36
Chorioretinal Shunt Vessel in Eyes with Central Retinal Vein Occlusion after Radial Optic Neurotomy. ( 30143093 )
2018
37
Combined bilateral ophthalmic artery occlusion & central retinal vein occlusion from presumed giant cell arteritis. ( 30148234 )
2018
38
Central retinal vein occlusion associated with vemurafenib use in metastatic skin melanoma. ( 30173784 )
2018
39
Bilateral simultaneous central retinal vein occlusion in hyperviscosity retinopathy treated with systemic immunosuppressive therapy only. ( 30182070 )
2018
40
Central Retinal Vein Occlusion with Chorioretinal Folds Secondary to Active Thyroid Eye Disease. ( 30243336 )
2018
41
Analysis of Morphologic and Functional Outcomes in Macular Edema due to Central Retinal Vein Occlusion Treated with Intravitreal Dexamethasone Implant. ( 30271628 )
2018
42
Treatment of Central Retinal Vein Occlusion-A New Look at a Blast From the Past. ( 30347024 )
2018
43
Two-Year Efficacy of Ranibizumab Plus Laser-Induced Chorioretinal Anastomosis vs Ranibizumab Monotherapy for Central Retinal Vein Occlusion: A Randomized Clinical Trial. ( 30347030 )
2018
44
Effect of aflibercept on persistent macular edema secondary to central retinal vein occlusion. ( 30361176 )
2018
45
IL-18 and S100A12 Are Upregulated in Experimental Central Retinal Vein Occlusion. ( 30366444 )
2018
46
Efficacy and Safety of an Aflibercept Treat-and-Extend Regimen in Treatment-Naïve Patients with Macular Oedema Secondary to Central Retinal Vein Occlusion (CRVO): A Prospective 12-Month, Single-Arm, Multicentre Trial. ( 30405907 )
2018
47
Association of Disorganization of Retinal Inner Layers with Ischemic Index and Visual Acuity in Central Retinal Vein Occlusion. ( 30511035 )
2018
48
Deep Neural Network-Based Method for Detecting Central Retinal Vein Occlusion Using Ultrawide-Field Fundus Ophthalmoscopy. ( 30515316 )
2018
49
Supernormal Flicker ERGs in Eyes With Central Retinal Vein Occlusion: Clinical Characteristics, Prognosis, and Effects of Anti-VEGF Agent. ( 30550616 )
2018
50
Unilateral central retinal vein occlusion as a first manifestation of diabetes mellitus in a ten-year-old girl. ( 30581309 )
2018

Variations for Central Retinal Vein Occlusion

Expression for Central Retinal Vein Occlusion

Search GEO for disease gene expression data for Central Retinal Vein Occlusion.

Pathways for Central Retinal Vein Occlusion

Pathways related to Central Retinal Vein Occlusion according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.73 APOH F2 F5 SERPINC1 VEGFA
2
Show member pathways
11.98 F2 F5 LOXL1 SERPINC1
3
Show member pathways
11.88 F2 IL6 MTHFR
4
Show member pathways
11.53 F2 F5 SERPINC1
5 11.16 IL6 VEGFA
6 11.11 IL6 VEGFA
7 10.94 F2 F5 SERPINC1
8 10.9 IL6 MTHFR
9 10.74 SERPINC1 VEGFA

GO Terms for Central Retinal Vein Occlusion

Cellular components related to Central Retinal Vein Occlusion according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.56 F2 F5 IL6 SERPINC1
2 extracellular region GO:0005576 9.56 APOH F2 F5 IL6 LOXL1 SERPINC1
3 collagen-containing extracellular matrix GO:0062023 9.46 APOH LOXL1 SERPINC1 SERPINF1
4 extracellular space GO:0005615 9.23 APOH F2 F5 IL6 LOXL1 SERPINC1

Biological processes related to Central Retinal Vein Occlusion according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 blood coagulation GO:0007596 9.63 F2 F5 SERPINC1
2 lactation GO:0007595 9.52 SERPINC1 VEGFA
3 blood circulation GO:0008015 9.51 F5 MTHFR
4 platelet degranulation GO:0002576 9.5 APOH F5 VEGFA
5 acute-phase response GO:0006953 9.49 F2 IL6
6 positive regulation of JAK-STAT cascade GO:0046427 9.48 F2 IL6
7 negative regulation of endothelial cell migration GO:0010596 9.43 APOH SERPINF1
8 blood coagulation, intrinsic pathway GO:0007597 9.4 APOH F2
9 positive regulation of blood coagulation GO:0030194 9.37 APOH F2
10 hemostasis GO:0007599 9.33 F2 F5 SERPINC1
11 negative regulation of fibrinolysis GO:0051918 9.26 APOH F2
12 cellular protein metabolic process GO:0044267 9.26 F2 F5 IL6 SERPINC1
13 regulation of blood coagulation GO:0030193 8.8 APOH F2 SERPINC1

Molecular functions related to Central Retinal Vein Occlusion according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.13 F2 IL6 VEGFA
2 heparin binding GO:0008201 8.92 APOH F2 SERPINC1 VEGFA

Sources for Central Retinal Vein Occlusion

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....